The lungs in systemic sclerosis (scleroderma): A review and new information

Seminars in Arthritis and Rheumatism

Volumn 17, Issue 4, 1988, Pages 271-283

  McCarthy, D S ^a   Baragar, F D ^b   Dhingra, S ^a   Sigurdson, M ^a   Sutherland, J B ^c   Rigby, M ^c   Martin, L ^b  

^a Department of Pediatrics and Child Health   (Canada)

^b Section of Rheumatology   (Canada)

^c Department of Radiology ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREATHING MUSCLE; CYTOLOGY; HUMAN; LUNG; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RADIOGRAPHY; REVIEW; SYSTEMIC SCLEROSIS;

BRONCHOALVEOLAR LAVAGE FLUID; HUMAN; LUNG; LUNG DISEASES; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY MUSCLES; SCLERODERMA, SYSTEMIC;

EID: 0024010967     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(88)90012-1     Document Type: Review

References (97)

1. Cancer and systemic sclerosis An epidemiological study
2. The effect of d-pencillamine on pulmonary findings in systemic sclerosis
3. Pulmonary involvement in systemic sclerosis (scleroderma)
4. Lung inflammation in scleroderma: Clinical, radiological, physiologic and cytopathological features
5. Evidence of chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis
6. Lung function in PSS is dominated by poorly compliant lung and stiff airways
7. Incidence of lung cancer in systemic sclerosis
8. Systemic sclerosis and malignancy—Are they related?
9. Sustained benefit of Verapamil in pulmonary hypertension with systemic sclerosis
10. Pulmonary vasculitis response during Raynaud's phenomenon in progressive systemic sclerosis
11. Roles of inflammation in the lung disease of systemic sclerosis; comparison with idiopathic pulmonary fibrosis
12. Interstitial lung disease in scleroderma Immune complexes in sera and bronchoalveolar lavage fluid
13. Pulmonary hypertension in the crest syndrome variant of systemic sclerosis
14. Sublcinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage; Relationship between alveolitis and subsequent changes in lung function
15. Alph-1 antitrypsin phenotypes, including M subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis
16. Bronchoalveolar lavage analysis of interstitial lung disease in CREST syndrome
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
18. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma)
19. Scleroderma and sclerodermalike disorders
20. Scleroderma (systemic sclerosis)
21. The relations between structural changes in small airways and pulmonary function tests
22. Idiopathic pulmonary fibrosis—Clinical histologic radiographic physiologic scintigraphic cytologic and biochemical aspects
23. Progressive systemic sclerosis Visceral manifestations in genealized scleroderma
24. Lung involvement in the connectivetissue disorders
25. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma
26. Pulmonary function in scleroderma. Its relation to changes in the chest roentgenogram and the skin of the thorax
27. Analysis of twenty-seven cases of progessive systemic sclerosis (including two with combined systemic lupus erythematosus) and a review of the literature
28. Pulmonary manifestations of progressive systemic sclerosis
29. Lung function in patients with systemic sclerosis
30. Roentgen manifestations in progressive systemic sclerosis (diffuse scleroderma)
31. The lung in scleroderma
32. The pulmonary manifestations of generalized scleroderma (progressive systemic sclerosis)
33. A case of slowly advancing scleroderma attended by cardiac and gastric disorders
34. Progressive systemic sclerosis (or visceral scleroderma): Review of the literature and report of cases
35. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma
36. Scleroderma Relation of pulmonary changes to oesophageal disease
37. Pulmonary scleroderma
38. The pathophysiology of scleroderma involving the heart and respiratory system
39. Roentgen findings in the “collagen” diseases
40. Discussion
41. Gastroesophageal reflux in esophageal scleroderma: Diagnosis and implications
42. Progressive systemic sclerosis Visceral manifestations in generalized scleroderma
43. Pathologic observations in systemic sclerosis (scleroderma)
44. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
45. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
46. Pulmonary fibrosis and terminal bronchiolar (“alveolar-cell”) carcinoma in scleroderma
47. The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs
48. Cancer of the lung in progressive systemic sclerosis
49. Pulmonary function in scleroderma
50. Pulmonary function in scleroderma
51. Site and nature of airway obstruction in chronic obstructive lung disease
52. Small airways disease in progressive systemic sclerosis (PSS)
53. Normal standards for ventilatory function using an automated wedge spirometer
54. Respiratory function tests: Normal values of median altitudes and the prediction of normal results
55. The pulmonary diffusing capacity in normal subjects
56. Progressive systemic sclerosis; pulmonary involvement
57. Lung function and the response to exercise in systemic sclerosis
58. Factors limiting exercise performance in progressive systemic sclerosis
59. Improved technique for estimating pleural pressure from oesophageal ballons
60. Lung distensibility; the static pressure-volume curve of the lungs and it's use in clinical assessment
61. An early pulmonary physiologic abnormality in progressive systemic sclerosis (diffuse scleroderma)
62. Frequency dependence of compliance as a test for obstruction in the small airways
63. Regional pulmonary function studies with zenon-133
64. Zenon-133 ventilation and perfusion study in bronchiectasis
65. Regional ventilation-perfusion and hypoxia in cryptogenic fibrosing alveolitis
66. Muscle disease in progressive systemic sclerosis. Diagnostic and therapeutic considerations
67. Respiratory muscle function and ventilatory control I. In patients with motor neuron II. In patients with myotonic dystrophy
68. Hypoventilatory respiratory failure in a patient with generalized scleroderma
69. Raynaud's phenomenon of the lung
70. Vascular reactivity and pulmonary hypertension in systemic sclerosis
71. Abnormality of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis
72. The effects of cold exposure indiffusing capacity in patients with Raynaud's phenomenon
73. Lung volume and pulmonary dynamics in Raynaud's disease Effect of exposure to cold
74. Analysis of cellular and protein content of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
75. Lung involvement in scleroderma
76. Bronchoalveolar lavage (BAL) analysis of scleroderma lung disease
77. Bronchoalveolar lavage (BAL) and 67 Ga studies in scleroderma (PSS) lung disease
78. Progressive systemic sclerosis: Management
79. Serial changes in scleroderma and idiopathic interstitial lung disease
80. Progressive systemic sclerosis: Management
81. Corticotrophin and cortisone in the treatment of scleroderma
82. Use of para-aminobenzoic acid in dermatomyositis and scleroderma. Report of six cases AMA
83. Treatment of scleroderma, sclerodactylia and calcinosis by chelation (EDTA)
84. Use of relaxin in the treatment of scleroderma
85. Epidemiology of systemic sclerosis (scleroderma)
86. Diffuse systemic scleroderma. A comparison with acrosclerosis
87. Survival with systemic sclerosis (scleroderma). Life-table analysis of clinical and dermographic factors in 309 patients
88. The natural history of progressive systemic sclerosis (diffuse scleroderma)
89. Epidemiology of fatal systemis sclerosis (diffuse scleroderma). A 15-year survey in Baltimore
90. Progressive systemic sclerosis (scleroderma)
91. Rapid onset of lung involvement in progressive systemic sclerosis
92. Serial pulmonary function in systemic sclerosis
93. Serial pulmonary function tests in progressive systemic sclerosis
94. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis
95. Respiratory function in the aged
96. Bronchoalveolar lavage in interstitial lung disease